학술논문

Active Pulmonary Tuberculosis During Interferon Beta-1a Therapy in a Child with Multiple Sclerosis: A Case Report
CASE REPORT
Document Type
Report
Source
Cam ve Sakura Medical Journal. December 2023, Vol. 3 Issue 3, p116, 4 p.
Subject
Care and treatment
Usage
Health aspects
Interferon beta -- Health aspects -- Usage
Biological response modifiers -- Usage -- Health aspects
Child health -- Usage -- Health aspects
Viral antigens -- Usage -- Health aspects
Patient compliance -- Usage -- Health aspects
Multiple sclerosis -- Care and treatment
Pulmonary tuberculosis -- Care and treatment
Teriflunomide -- Health aspects -- Usage
Pediatric neurology -- Health aspects -- Usage
Children -- Health aspects
Language
English
Abstract
What is known on this subject? Beta interferons are the first class of disease-modifying therapies, and their immunomodulatory effects are achieved by inhibiting T-cell activation and proliferation. However, modulation and [...]
Interferon (IFN) beta (p) is a potent anti-inflammatory and immunomodulatory agent that is used for treating patients with multiple sclerosis (MS). In this study, we present the case of a 15-year-old female patient diagnosed with MS and treated with IFN [beta]-1a for six months who was referred to the emergency department with complaints of fatigue, fever, and coughing. She was diagnosed with pulmonary tuberculosis (TB). IFN [beta]-1a therapy was stopped and anti-TB treatment was initiated. After nine months of therapy, she recovered from TB. This case presented with a rare side effect during the treatment of pediatric-onset MS with immunomodulatory drugs, demonstrating the importance of screening and close follow-up of patients with TB. Keywords: Case report, interferon beta, multiple sclerosis, pediatric neurology, tuberculosis